Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aviral Singh

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Neuroendocrinology|July 21, 2017
Morphological and Functional Imaging for Detecting and Assessing the Resectability of Neuroendocrine Liver MetastasesMaxime Ronot, Ashley K Clift, Richard P Baum, et al.
The British Journal of Radiology|May 16, 2018
Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigenHarshad R Kulkarni, Aviral Singh, Thomas Langbein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2016
PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013Harshad R Kulkarni, Aviral Singh, Christiane Schuchardt, et al.
Plos One|September 10, 2016
Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting PeptidesPeter Kletting, Christiane Schuchardt, Harshad R Kulkarni, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 14, 2017
<sup>177</sup>Lu-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical ResultsRichard P Baum, Aviral Singh, Christiane Schuchardt, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 18, 2017
First-in-Human PET/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced <sup>44</sup>Sc-DOTATOC: A Proof-of-Concept StudyAviral Singh, Nicholas P van der Meulen, Cristina Müller, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 23, 2016
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and EfficacyRichard P Baum, Harshad R Kulkarni, Christiane Schuchardt, et al.
Oncotarget|May 10, 2019
<sup>177</sup>Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancerFinn Edler von Eyben, Aviral Singh, Jingjing Zhang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 6, 2016
Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical ResultsBerthold A Nock, Aikaterini Kaloudi, Emmanouil Lymperis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 10, 2019
Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 PatientsElse A Aalbersberg, Daphne M V Huizing, Iris Walraven, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Neuroendocrinology|July 21, 2017
Morphological and Functional Imaging for Detecting and Assessing the Resectability of Neuroendocrine Liver MetastasesMaxime Ronot, Ashley K Clift, Richard P Baum, et al.
The British Journal of Radiology|May 16, 2018
Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigenHarshad R Kulkarni, Aviral Singh, Thomas Langbein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2016
PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013Harshad R Kulkarni, Aviral Singh, Christiane Schuchardt, et al.
Plos One|September 10, 2016
Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting PeptidesPeter Kletting, Christiane Schuchardt, Harshad R Kulkarni, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 14, 2017
<sup>177</sup>Lu-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical ResultsRichard P Baum, Aviral Singh, Christiane Schuchardt, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 18, 2017
First-in-Human PET/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced <sup>44</sup>Sc-DOTATOC: A Proof-of-Concept StudyAviral Singh, Nicholas P van der Meulen, Cristina Müller, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 23, 2016
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and EfficacyRichard P Baum, Harshad R Kulkarni, Christiane Schuchardt, et al.
Oncotarget|May 10, 2019
<sup>177</sup>Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancerFinn Edler von Eyben, Aviral Singh, Jingjing Zhang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 6, 2016
Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical ResultsBerthold A Nock, Aikaterini Kaloudi, Emmanouil Lymperis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 10, 2019
Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 PatientsElse A Aalbersberg, Daphne M V Huizing, Iris Walraven, et al.
Pageof 6